Answers are grounded in this paper and cite their sources.
Mitochondrial dysfunction is increasingly implicated in psychiatric disorders, yet the regulatory mechanisms linking brain-expressed mitochondrial genes to disease risk remain unclear. To investigate these mechanisms, we employed an integrative multi-omics approach combining brain-derived DNA methylation, gene expression, and protein abundance quantitative trait locus (QTL) datasets to evaluate genetically predicted associations of mitochondria related molecular traits with schizophrenia (SCZ), bipolar disorder (BD), major depressive disorder (MDD), cross-disorder phenotypes, and clinical subtypes. Summary-data-based Mendelian randomization (SMR), Heterogeneity in dependent instruments (HEIDI) testing, and Bayesian colocalization analyses were applied, followed by a study-specific three-tier framework to prioritize potential putative causal genes. Our analyses prioritized ACADVL and SLC25A24 as Tier 1 genes for SCZ, COX11 as a Tier 2 gene for SCZ, and DLST, ENDOG, and PDF as Tier 3 genes for SCZ. ENDOG and PDF were also prioritized for the BD-SCZ cross-disorder phenotype. Further SMR analyses across molecular layers supported ENDOG as a methylation-linked regulatory signal, whereas expression-to-protein associations for COX11 and SLC25A24 showed colocalization support but did not meet the HEIDI criterion. Single-cell analyses suggested context-dependent ENDOG effects across immune cell types. Together, these findings support the involvement of mitochondria-related genes across molecular layers in psychiatric disorders and identify genetically supported candidate genes that warrant experimental validation.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: